Phase I/II Trial Of Imatinib Mesylate; (Gleevec; STI571) In Treatment Of Recurrent Oligodendroglioma And Mixed Oligoastrocytoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 03 Dec 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 03 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.